2024. Real-World Effectiveness of Upadacitinib in Moderate‑to‑Severe Atopic Dermatitis (AD): Results From Longitudinal Analyses of the CorEvitas AD Registry. SKIN The Journal of Cutaneous Medicine. 8, 6 (Nov. 2024), s450. DOI:https://doi.org/10.25251/skin.8.supp.450.